Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel Free CRDL Stock Alerts

Cardiol Therapeutics (CRDL) Competitors

Cardiol Therapeutics logo
C$2.98 -0.03 (-1.00%)
As of 09/3/2026 04:00 PM Eastern
Compare

CRDL vs. DHT.UN, THCX, GUD, TLRY, and CMED

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Knight Therapeutics (GUD), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to DRI Healthcare Trust?

Cardiol Therapeutics (TSE:CRDL) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, DRI Healthcare Trust had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for DRI Healthcare Trust and 0 mentions for Cardiol Therapeutics. DRI Healthcare Trust's average media sentiment score of 1.49 beat Cardiol Therapeutics' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiol Therapeutics Neutral
DRI Healthcare Trust Positive

DRI Healthcare Trust has a net margin of 5.02% compared to Cardiol Therapeutics' net margin of 0.00%. DRI Healthcare Trust's return on equity of 2.06% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.13% -54.15%
DRI Healthcare Trust 5.02%2.06%4.22%

DRI Healthcare Trust has higher revenue and earnings than Cardiol Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A
DRI Healthcare TrustC$172.34M5.57C$9.73M-C$0.80N/A

DRI Healthcare Trust has a consensus target price of C$25.20, suggesting a potential upside of 44.33%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts clearly believe DRI Healthcare Trust is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

0.0% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cardiol Therapeutics has a beta of 0.270267, meaning that its share price is 73% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, meaning that its share price is 63% less volatile than the broader market.

Summary

DRI Healthcare Trust beats Cardiol Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
Hydropothecary Neutral
Cardiol Therapeutics Neutral

0.0% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hydropothecary's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HydropothecaryN/A N/A N/A
Cardiol Therapeutics N/A -180.13%-54.15%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HydropothecaryN/AN/AN/AN/AN/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A

Summary

Hydropothecary and Cardiol Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Knight Therapeutics?

Cardiol Therapeutics (TSE:CRDL) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

0.0% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Knight Therapeutics had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cardiol Therapeutics. Knight Therapeutics' average media sentiment score of 0.95 beat Cardiol Therapeutics' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Knight Therapeutics Positive

Knight Therapeutics has a net margin of 2.72% compared to Cardiol Therapeutics' net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.13% -54.15%
Knight Therapeutics 2.72%1.91%0.51%

Knight Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A
Knight TherapeuticsC$547.31M1.80-C$30.73MC$0.1566.93

Cardiol Therapeutics has a beta of 0.270267, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, indicating that its stock price is 129% less volatile than the broader market.

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 5.38%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Knight Therapeutics beats Cardiol Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Tilray Brands?

Cardiol Therapeutics (TSE:CRDL) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Cardiol Therapeutics has higher earnings, but lower revenue than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A
Tilray BrandsC$915.45M0.94-C$183.24M-C$1.09N/A

In the previous week, Tilray Brands' average media sentiment score of 0.71 beat Cardiol Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Tilray Brands Positive

Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -15.22%. Tilray Brands' return on equity of -8.85% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.13% -54.15%
Tilray Brands -15.22%-8.85%-1.41%

0.0% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Tilray Brands shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 0.7% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.270267, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.215277, indicating that its stock price is 222% more volatile than the broader market.

Tilray Brands has a consensus price target of C$13.30, suggesting a potential upside of 113.48%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts plainly believe Tilray Brands is more favorable than Cardiol Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Tilray Brands beats Cardiol Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CanniMed TherapeuticsN/AN/AN/AN/AN/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.34N/A

0.0% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CanniMed TherapeuticsN/A N/A N/A
Cardiol Therapeutics N/A -180.13%-54.15%

In the previous week, CanniMed Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
CanniMed Therapeutics Neutral
Cardiol Therapeutics Neutral

Summary

CanniMed Therapeutics and Cardiol Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDL vs. The Competition

Export
MetricCardiol TherapeuticsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$348.13MC$12.25BC$7.26BC$12.57B
Dividend YieldN/A2.59%2.53%6.25%
P/E Ratio-8.76787.27273.2939.47
Price / SalesN/A753.79613.459.82
Price / Cash0.9894.8077.8282.29
Price / Book14.2512.3312.894.71
Net Income-C$42.93MC$2.82BC$3.47BC$299.09M
7 Day Performance10.37%2.59%0.60%-0.31%
1 Month Performance55.21%6.95%5.73%3.12%
1 Year Performance94.77%9.45%25.35%28.73%

Cardiol Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDL
Cardiol Therapeutics
N/AC$2.98
-1.0%		N/A+97.4%C$348.13MN/AN/A20
DHT.UN
DRI Healthcare Trust
2.7232 of 5 stars		C$17.80
-0.4%		C$25.20
+41.6%		+19.8%C$978.34MC$172.34MN/AN/A
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
GUD
Knight Therapeutics
0.994 of 5 stars		C$9.66
+0.3%		C$9.50
-1.7%		+55.2%C$948.92MC$547.31M64.40725
TLRY
Tilray Brands
1.4211 of 5 stars		C$6.67
+3.6%		C$13.30
+99.4%		-61.8%C$917.67MC$915.45MN/A2,650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel